Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Other Accumulated Expenses (2024 - 2025)

Evommune (EVMN) has disclosed Other Accumulated Expenses for 2 consecutive years, with $364000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 36.47% to $364000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $364000.0, a 36.47% decrease, with the full-year FY2025 number at $364000.0, down 36.47% from a year prior.
  • Other Accumulated Expenses was $364000.0 for Q4 2025 at Evommune, down from $449000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $573000.0 in Q4 2024 to a low of $364000.0 in Q4 2025.